Pulmatrix and Eos SENOLYTIX Unite to Revolutionize Mitochondrial Therapies for Healthspan Improvement Pulmatrix and Eos SENOLYTIX have announced a merger to become a leader in gerotherapeutics, focusing on novel therapies for aging-related diseases. The goal is to enhance healthspan through mitochondrial-focused treatments.

Pulmatrix and Eos SENOLYTIX Unite to Revolutionize Mitochondrial Therapies for Healthspan Improvement #United_States #Pulmatrix #Framingham,_Massachusetts #Eos_SENOLYTIX #PTC-2105

Pulmatrix Shifts Focus Following Termination of Merger with Cullgen Pulmatrix has announced it will pursue alternative merger opportunities after the termination of its planned merger with Cullgen, stemming from regulatory delays.

Pulmatrix Shifts Focus Following Termination of Merger with Cullgen #USA #Framingham #Pulmatrix #iSPERSE #Cullgen

Pulmatrix Reports Year-End Financial Results and Status of Merger with Cullgen in 2025 In its latest update, Pulmatrix discusses significant developments including financial outcomes for 2025 and insights on its merger with Cullgen.

Pulmatrix Reports Year-End Financial Results and Status of Merger with Cullgen in 2025 #United_States #Framingham #Pulmatrix #Cullgen #iSPERSE™

Pulmatrix and Cullgen Move Forward with Merger Plans Despite Exploring Alternatives Pulmatrix and Cullgen continue their merger discussions while also exploring other business opportunities. The companies aim for growth amidst regulatory challenges.

Pulmatrix and Cullgen Move Forward with Merger Plans Despite Exploring Alternatives #USA #Merger #Framingham #Pulmatrix #Cullgen

Pulmatrix Reports Q3 2025 Results and Strategic Divestiture Plans for Inhalation Assets Pulmatrix, Inc. has announced its Q3 2025 financial results and revealed plans for divesting assets, focusing on migraine and respiratory treatments through innovative inhalation technologies.

Pulmatrix Reports Q3 2025 Results and Strategic Divestiture Plans for Inhalation Assets #United_States #Framingham #Pulmatrix #Migraine #iSPERSE

Pulmatrix's Q2 2025 Financial Results and Strategy to Divest Inhalation Assets Pulmatrix, Inc. reveals its financial outcomes for the second quarter of 2025, alongside plans to divest its inhalation technology assets amid a proposed merger.

Pulmatrix's Q2 2025 Financial Results and Strategy to Divest Inhalation Assets #United_States #Framingham #Pulmatrix #iSPERSE #Cullgen

Pulmatrix Reports 2025 Financial Results and Strategic Asset Divestment Plan Pulmatrix, Inc. announces its first quarter financial outcomes for 2025, highlighting a proposed merger with Cullgen and plans for asset divestment.

Pulmatrix Reports 2025 Financial Results and Strategic Asset Divestment Plan #USA #Framingham #Pulmatrix #Cullgen #iSPERSE™

Pulmatrix Reports Financial Results and Plans for Divestment Amid Merger with Cullgen Pulmatrix, Inc. has shared its fourth quarter 2024 financial results, revealing a divestment strategy coinciding with a proposed merger with Cullgen.

Pulmatrix Reports Financial Results and Plans for Divestment Amid Merger with Cullgen #United_States #Framingham #Pulmatrix #iSPERSE #Cullgen

Halper Sadeh LLC Investigates Triumph Group and Others on Shareholder Rights Halper Sadeh LLC is probing several companies, including Triumph Group and Pulmatrix, alleging potential securities law violations affecting shareholders.

Halper Sadeh LLC Investigates Triumph Group and Others on Shareholder Rights #United_States #New_York #Halper_Sadeh #TRIUMPH_Group #Pulmatrix